RecruitingPhase 1Phase 2NCT07363382

The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer

The Value of Gastrin-Releasing Peptide Receptor (GRPR) PET Imaging for Diagnosis and Staging in Prostate Cancer

Sponsor

First Affiliated Hospital of Fujian Medical University

Enrollment

6 participants

Start Date

Dec 20, 2025

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer (Adenocarcinoma)

Summary

The gastrin-releasing peptide receptor (GRPR) is highly expressed in prostate cancer (77%-100%). Numerous studies have confirmed that GRPR PET imaging has emerged as a significant molecular imaging modality in prostate cancer, particularly serving as a complementary tool to PSMA PET for addressing cases with negative or insufficient PSMA expression. It demonstrates substantial value in initial staging (especially in intermediate- and high-risk patients), detecting sites of biochemical recurrence, assessing metastatic lesions (notably in mCRPC), and guiding treatment decisions. 68Ga-G21 and 68Ga-G23 are two novel molecular probes targeting GRPR. This study aims to evaluate their biodistribution and diagnostic performance in prostate cancer and compare them with 68Ga-PSMA-11 PET imaging.

Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating a new type of PET scan imaging that targets a protein called GRPR (Gastrin-Releasing Peptide Receptor) to see how well it diagnoses and stages prostate cancer — helping doctors see where the cancer is and how far it has spread. **You may be eligible if...** - You have a confirmed diagnosis of prostate cancer (whether currently being treated or not) - You are able to provide written consent **You may NOT be eligible if...** - You have a known allergy to PSMA (a related imaging agent) - You have a medical condition that, in the doctor's opinion, would significantly interfere with the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG68Ga-G21

Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-G21. Tracer of 68Ga-G21 will be used to image lesions of prostate cancer by PET imaging.

DRUG68Ga-G23

Intravenous injection of one dosage of 111-148 MBq (3-4 mCi) 68Ga-G23. Tracer of 68Ga-G23 will be used to image lesions of prostate cancer by PET imaging.

Locations(1)

Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07363382

Related Trials

Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1

NCT075529221 location

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

NCT068443832 locations

Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria

NCT0748497124 locations

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

NCT06592924340 locations

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

NCT068012368 locations